Genes accionables para Warfarina
Warfarin Dosing and Pharmacogenetics
Introduction to Pharmacogenetic Analysis
- The lesson addresses whether pharmacogenetic analysis necessitates dose modification or alternative therapeutic options for patients based on their pharmacogenomics.
Mechanism of Action of Warfarin
- Warfarin, also known as Sintrom, is an anticoagulant that inhibits the enzyme VKORC1, crucial for converting oxidized vitamin K into its reduced form, which activates coagulation factors VII, IX, and X.
- The activation process involves adding carboxyl groups to these factors in the liver, enhancing their negative charge and facilitating binding to negatively charged platelets through calcium ions.
Specificity and Bioavailability Considerations
- Patients with a specific amino acid change (aspartic acid to tyrosine at position 36) in VKORC1 exhibit low enzyme expression; thus, increasing Warfarin dosage would be ineffective due to lack of target action.
- For patients with CYP2C9 polymorphisms (*1/*2 or *2/*3), metabolism of Warfarin is significantly reduced; particularly *1/*2 shows less than 40% metabolism leading to prolonged effects requiring lower doses or alternative anticoagulants.
Role of Modifier Polymorphisms
- Polymorphisms in CYP4F2 affect vitamin K levels by converting reduced vitamin K back to its inactive form; mutations can lead to higher active vitamin K levels necessitating dose adjustments for effective treatment.
- In cases where patients have low activity due to a mutation at position 433 (valine to methionine), it is reasonable to decrease the Warfarin dose due to increased active vitamin K availability.
Summary of Key Insights on Warfarin Treatment
- Analyzing patient-specific polymorphisms before administering Warfarin is critical as they can cause variations in drug response up to 20 times in potency. Excessive inhibition increases hemorrhagic risk while insufficient dosing raises thrombosis risk. Thus, careful monitoring is essential for maintaining INR levels between 2 and 3.5.
- Current preferences lean towards treatments like selective factor X inhibitors (e.g., apixaban) that do not require constant monitoring compared to traditional methods involving Warfarin due to its narrow therapeutic margin requiring frequent adjustments.
Importance of Comprehensive Assessment
- While pharmacogenetic testing plays a vital role in treatment efficacy, other factors such as dietary intake of vitamin K and liver function must also be considered as they can significantly influence treatment outcomes.